Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,200 across all filing types
Latest filing 2021-02-04 Capital/Financing Update
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the company's decision to demerge its biotech business under Stelis Biopharma and related strategic and board changes. It does not contain financial statements, detailed financial analysis, or regulatory filings. It is an announcement of a corporate transaction and strategic update rather than a formal report or regulatory filing. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to corporate restructuring and capital strategy.
2021-02-04 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 100% confidence The document is a formal letter addressed to stock exchanges announcing the allotment of shares under the company's ESOP (Employee Stock Option Plan). It specifies the number of shares allotted, the increase in paid-up share capital, and confirms that the new shares rank equally with existing shares. There is no financial data, report, or detailed analysis present. The content is an announcement of a capital change due to share allotment. According to the filing definitions, announcements regarding new share issues or capital changes fall under the category 'Share Issue/Capital Change' (SHA). The document length is short and focused solely on this capital change, confirming it is not a full report or other filing type.
2021-02-04 English
Financial Result Updates
Regulatory Filings
2021-02-04 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a notification about an upcoming earnings call to discuss un-audited financial results for the quarter and nine months ended December 31, 2020. It includes details about the call timing, dial-in numbers, and speakers, but does not contain the actual financial results or a transcript of the call. The document length is 3158 characters, which is relatively short and consistent with an announcement rather than a full report or transcript. Therefore, this document is best classified as a Call Transcript (CT) announcement, but since it does not contain the transcript itself, it is an announcement of the call. However, given the options, the closest and most appropriate classification is Call Transcript (CT) because it relates directly to the earnings call event and its transcript will be posted later. Confidence is high due to clear references to the earnings call and transcript posting.
2021-02-02 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the intimation of a Board Meeting scheduled to consider and approve unaudited financial results for a quarter and nine months period. It includes a reference to a previous letter and encloses copies of newspaper advertisements about the Board Meeting. The document is short (1284 characters) and serves as a notification or announcement rather than containing actual financial data or detailed report content. It does not contain the financial results themselves, only an intimation about the meeting and publication of advertisements. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit into other specific categories like Interim Report or Earnings Release.
2021-01-29 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a short announcement addressed to stock exchanges informing about a scheduled Board Meeting to consider and approve unaudited financial results for a specific quarter and nine months period. It also mentions the closure of the trading window as per insider trading regulations. There is no actual financial data or detailed report included, only a notification of the upcoming board meeting and related compliance information. The document length is only 1235 characters, which is quite short and fits the pattern of an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not contain the financial results themselves or detailed management discussion.
2021-01-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.